212 related articles for article (PubMed ID: 33396393)
1. Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer.
Wang TH; Wu CC; Huang KY; Leu YL; Yang SC; Chen CL; Chen CY
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396393
[TBL] [Abstract][Full Text] [Related]
2. Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin.
Huang KY; Wang TH; Chen CC; Leu YL; Li HJ; Jhong CL; Chen CY
Biomolecules; 2021 Aug; 11(9):. PubMed ID: 34572484
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations in epidermal growth factor receptor-tyrosine kinase inhibitor-naïve non-small cell lung carcinoma.
Yamaura T; Muto S; Mine H; Takagi H; Watanabe M; Ozaki Y; Inoue T; Fukuhara M; Okabe N; Matsumura Y; Hasegawa T; Osugi J; Hoshino M; Higuchi M; Shio Y; Suzuki H
Oncol Lett; 2020 Jun; 19(6):4169-4176. PubMed ID: 32391110
[TBL] [Abstract][Full Text] [Related]
4. Two case reports of non-small cell lung cancer patients harboring acquired
Song Z; Ren G; Hu L; Wang X; Song J; Jia Y; Zhao G; Zang A; Du H; Sun Y; Zhao X
Ann Transl Med; 2022 Jun; 10(12):719. PubMed ID: 35845537
[TBL] [Abstract][Full Text] [Related]
5. Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation
Lai M; Zhang T; Chen H; Song P; Tong L; Chen J; Liu Y; Ning Y; Feng F; Li Y; Tang H; Chen Y; Fang Y; Lu X; Geng M; Ding K; Yu K; Ding J; Xie H
J Cancer; 2023; 14(1):152-162. PubMed ID: 36605493
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR
Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
[TBL] [Abstract][Full Text] [Related]
7. Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
Hidaka N; Iwama E; Kubo N; Harada T; Miyawaki K; Tanaka K; Okamoto I; Baba E; Akashi K; Sasaki H; Nakanishi Y
Lung Cancer; 2017 Jun; 108():75-82. PubMed ID: 28625653
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045.
Zhao P; Yao MY; Zhu SJ; Chen JY; Yun CH
Biochem Biophys Res Commun; 2018 Jul; 502(3):332-337. PubMed ID: 29802850
[TBL] [Abstract][Full Text] [Related]
9. The reversible fourth-generation EGFR tyrosine kinase inhibitor OBX02-011 overcomes C797S-mediated resistance in lung cancer.
Choi YJ; Kim DS; Hoon Sung Y; Kim DH; Im K; Lee H; Lee CW; Cho J; Min J; Woo DC; Kim SE; Lee S; Kong YJ; Ryu HC; Kim JS; Rengasamy R; Ji W; Choi CM; Lee JC; Rho JK
Cancer Res; 2022 Jun; ():. PubMed ID: 35700239
[TBL] [Abstract][Full Text] [Related]
10. Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer.
Lin CY; Huang KY; Lin YC; Yang SC; Chung WC; Chang YL; Shih JY; Ho CC; Lin CA; Shih CC; Chang YH; Kao SH; Yang PC
Cancer Lett; 2021 Jun; 508():76-91. PubMed ID: 33775711
[TBL] [Abstract][Full Text] [Related]
11. Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M,
Chang Y; Liu S; Jiang Y; Hua L; Wen L
Respir Med Case Rep; 2022; 36():101582. PubMed ID: 35106279
[TBL] [Abstract][Full Text] [Related]
12. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.
Patel H; Pawara R; Surana S
Comput Biol Chem; 2018 Jun; 74():167-189. PubMed ID: 29627693
[TBL] [Abstract][Full Text] [Related]
13. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
Niederst MJ; Hu H; Mulvey HE; Lockerman EL; Garcia AR; Piotrowska Z; Sequist LV; Engelman JA
Clin Cancer Res; 2015 Sep; 21(17):3924-33. PubMed ID: 25964297
[TBL] [Abstract][Full Text] [Related]
14. Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations.
Duggirala KB; Lee Y; Lee K
Biomol Ther (Seoul); 2022 Jan; 30(1):19-27. PubMed ID: 34074804
[TBL] [Abstract][Full Text] [Related]
15. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
16. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
Kobayashi Y; Azuma K; Nagai H; Kim YH; Togashi Y; Sesumi Y; Chiba M; Shimoji M; Sato K; Tomizawa K; Takemoto T; Nishio K; Mitsudomi T
Mol Cancer Ther; 2017 Feb; 16(2):357-364. PubMed ID: 27913578
[TBL] [Abstract][Full Text] [Related]
17. Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review.
Mansour MA; AboulMagd AM; Abbas SH; Abdel-Rahman HM; Abdel-Aziz M
RSC Adv; 2023 Jun; 13(27):18825-18853. PubMed ID: 37350862
[TBL] [Abstract][Full Text] [Related]
18. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.
Wang X; Goldstein D; Crowe PJ; Yang JL
Onco Targets Ther; 2016; 9():5461-73. PubMed ID: 27660463
[TBL] [Abstract][Full Text] [Related]
19. Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer.
Sun P; Qu Y; Wang Y; Wang J; Wang X; Sheng J
J Cancer; 2021; 12(13):3900-3908. PubMed ID: 34093797
[TBL] [Abstract][Full Text] [Related]
20. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
